GSK
GSK
853 hedge funds and large institutions have $11.6B invested in GSK in 2024 Q4 according to their latest regulatory filings, with 110 funds opening new positions, 284 increasing their positions, 323 reducing their positions, and 150 closing their positions.
339% more call options, than puts
Call options by funds: $460M | Put options by funds: $105M
98% more capital inflows, than outflows
Capital inflows: $2.45B | Capital outflows: $1.24B
20% more funds holding in top 10
Funds holding in top 10: 10 → 12 (+2)
1.57% more ownership
Funds ownership: 15.19% → 16.75% (+1.6%)
6% less funds holding
Funds holding: 905 → 853 (-52)
12% less repeat investments, than reductions
Existing positions increased: 284 | Existing positions reduced: 323
27% less first-time investments, than exits
New positions opened: 110 | Existing positions closed: 150
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$857M |
| 2 |
Primecap Management
Pasadena,
California
|
+$375M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$209M |
| 4 |
Goldman Sachs
New York
|
+$83.3M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$72.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Provident Trust Company
Waukesha,
Wisconsin
|
-$162M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$131M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$98.9M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$91.7M |
| 5 |
Morgan Stanley
New York
|
-$80.2M |
GSK Hedge Fund Activity: Q4 2024 in Review
853 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2024, worth a combined $11.6B — down 8.5% from $12.7B a quarter earlier.
Sellers outnumbered buyers: 150 funds closed out of GSK and 110 opened new positions — a net loss of 40 holders — while 323 trimmed existing stakes and 284 added.
The largest buyer was Fidelity Investments, adding an estimated $857M. The largest seller was Provident Trust Company, exiting entirely with an estimated $162M sold.
- 853 institutional investors held GSK (GSK) as of Q4 2024, down from 905 in Q3 2024.
- Funds reported $11.6B of GSK stock for Q4 2024, down 8.5% quarter-over-quarter.
- 110 funds opened new GSK positions in Q4 2024 and 150 closed out, a net change of -40 holders.
- The largest GSK buyer in Q4 2024 was Fidelity Investments, an estimated $857M added.
- The largest GSK seller in Q4 2024 was Provident Trust Company, an estimated $162M sold.
Based on aggregated 13F filings for Q4 2024.